VR Adviser, LLC Q2 2022 Filing
Filed August 15, 2022
Portfolio Value
$554.1B
Holdings
28
Report Date
Q2 2022
Filing Type
13F-HR
All Holdings (28 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | 1T7Tricida Inc | 7,132,079 | $69.0B | 12.46% | |
| 2 | ACRSAclaris Therapeutics Inc | 4,563,962 | $63.7B | 11.50% | |
| 3 | —DBV Technologies SA | 9,300,000 | $46.3B | 8.35% | |
| 4 | RLMDRelmada Therapeutics Inc | 2,270,072 | $43.1B | 7.78% | |
| 5 | TVTXTravere Therapeutics Inc | 1,711,102 | $41.5B | 7.48% | |
| 6 | COGTCogent Biosciences Inc | 4,038,117 | $36.4B | 6.57% | |
| 7 | GHRSGH Research PLC | 3,185,573 | $31.8B | 5.74% | |
| 8 | TILInstil Bio Inc | 5,997,657 | $27.7B | 5.00% | |
| 9 | TCE2Celldex Therapeutics Inc | 865,116 | $23.3B | 4.21% | |
| 10 | VRDNViridian Therapeutics Inc | 1,852,919 | $21.4B | 3.87% | |
| 11 | VTGNUSDVistaGen Therapeutics Inc | 20,697,286 | $18.2B | 3.29% | |
| 12 | MRNS*Marinus Pharmaceuticals Inc | 3,156,803 | $15.3B | 2.76% | |
| 13 | WHWKAadi Bioscience Inc | 1,173,518 | $14.5B | 2.61% | |
| 14 | INZYInozyme Pharma Inc | 2,709,987 | $12.9B | 2.33% | |
| 15 | —Akouos Inc | 2,667,119 | $12.5B | 2.26% | |
| 16 | LIANYLianBio | 5,378,341 | $11.6B | 2.10% | |
| 17 | AVTEAerovate Therapeutics Inc | 590,408 | $9.2B | 1.67% | |
| 18 | TRVITrevi Therapeutics Inc | 3,050,022 | $8.6B | 1.55% | |
| 19 | 290AChinook Therapeutics Inc | 489,618 | $8.6B | 1.55% | |
| 20 | ANNXAnnexon Inc | 1,928,477 | $7.3B | 1.31% | |
| 21 | YB4PSavara Inc | 4,117,530 | $6.3B | 1.13% | |
| 22 | LYRALyra Therapeutics Inc | 924,170 | $5.2B | 0.94% | |
| 23 | PRVBUSDProvention Bio Inc | 1,118,653 | $4.5B | 0.81% | |
| 24 | ALTAltimmune Inc | 369,306 | $4.3B | 0.78% | |
| 25 | ATYRaTyr Pharma Inc | 1,398,889 | $4.0B | 0.71% | |
| 26 | —Affimed NV | 1,428,571 | $4.0B | 0.71% | |
| 27 | RLYBRallybio Corp | 268,532 | $2.0B | 0.37% | |
| 28 | XENEXenon Pharmaceuticals Inc | 30,000 | $913.0M | 0.16% |